AB Science has announced that the European Patent Office has issued a Notice of Allowance for a method patent (i.e. a medical use patent) for the treatment of severe systemic mastocytosis with its lead compound, masitinib.

This new European patent protects the
intellectual property of masitinib in this indication until October 2036.

More specifically, masitinib is intended for the treatment of patients with severely symptomatic systemic mastocytosis, including indolent and smouldering systemic mastocytosis sub-variants, who do not respond to optimal symptomatic treatment.

Notice of Acceptance (NOA) means that the European Patent Office intends to grant the patent application, EP3359195A1, after completion of certain steps in the formal procedure.

This is good news, as it proves once again that the masitinib platform is protected for a period ranging from 12 to 17 years, depending on the indication, which leaves sufficient time to carry
the program through to registration and to maximize revenues during the commercialization phase", said Alain Moussy, CEO of AB Science.

Masitinib has already been granted orphan drug status in mastocytosis by the FDA and the EMA.

Copyright (c) 2024 CercleFinance.com. All rights reserved.